Logo

Biosyngen’s BST02 Receives the US FDA’s Fast Track Designation to Treat Liver Cancer

Share this
Biosyngen

Biosyngen’s BST02 Receives the US FDA’s Fast Track Designation to Treat Liver Cancer

Shots:

  • The US FDA has granted FTD to the company’s BST02 for treating multiple types of liver cancer such as hepatocellular carcinoma and cholangiocarcinoma
  • BST02 is currently being evaluated in a P-I/II dose escalation & expansion study for its safety, tolerability, and initial efficacy for the treatment of locally advanced/metastatic liver cancer
  • The company’s BST02 is a T-cell therapy that employs the patient's own tumor infiltrating lymphocytes and has the potential of overcoming distance constraints because of its cryopreserved form and the reduced need for high interleukin-2 dosage

Ref: Biosyngen Image: Biosyngen

Related News:- BioCity Collaborated with AstraZeneca to Evaluate BC3402 + Imfinzi (durvalumab) for Advanced Hepatocellular Carcinoma in China

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions